ArticleJournal of circulating biomarkers
Association of hypertension and diabetes with COVID-19 severity in comparison to healthy patients.
Article in Journal of circulating biomarkers. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 2 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Prevalence of hypertension in severe vs. non-severe COVID-19: a systematic review and meta-analysis.Journal of human hypertension · 2026Pooled it
- Erratum in: Association of hypertension and diabetes with COVID-19 severity in comparison to healthy patients.Journal of circulating biomarkersArticle
Corrections and comments
- Erratum issued
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: The coronavirus is a novel pandemic disease that began in Wuhan, China, and further spread globally. Therefore, the aim of this retrospective work was to look at the clinical characteristics and outcomes of diabetic and blood pressure patients compared with a healthy patient who was infected with coronavirus disease (COVID-19). Methods: Data and outcomes were gathered from medical records and analyzed in 150 patients. The disease is frequently diagnosed via nucleic acid-based viral identification from swabs, sputum, or bronchial alveolar lavage fluid (BALF) using diagnostic reagents such as quantitative reverse transcription-polymerase chain reaction (RT-qPCR). COVID-19 chest radiographs were obtained, and clinical characteristics and outcomes were evaluated. In this study, we analyzed and compared the severity of the disease, its outcome, any associated complications, and clinical laboratory findings in COVID-19 patients between diabetic, hypertensive, and healthy individuals. Results and Conclusion: According to the findings, COVID-19 can cause a wide range of symptoms, which range from asymptomatic to severe respiratory problems and death. Diabetes appears to be one of the most significant comorbidities associated with a worse COVID-19 result. COVID-19 patients with diabetes (50 (33%) and hypertension (50 (33%)) had more ICU admissions compared with the non-diabetic and non-blood pressure patients (50 (33%)). During the treatment follow-up, 10 (6.6%) of the 150 patients passed away, 140 (93%) were released, 110 (73%) were discharged, and 30 (20%) kept in the hospital. Compared to non-diabetic and healthy COVID-19 patients, diabetic COVID-19 patients had a greater mortality rate.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.